Tuberculosis

Vaccine maker, Aeras Global TB Vaccine Foundation partner to develop new TB vaccine

Published in TB and Outbreaks Week, November 22nd, 2005

GlaxoSmithKline Biologicals (GSK Biologicals) and the Aeras Global TB Vaccine Foundation (Aeras) announced a new public-private partnership to develop GSK Biologicals' tuberculosis (TB) candidate vaccine Mtb72F/AS02A, which has shown promising results in preclinical studies.

In addition, the vaccine has shown a good safety and immunogenicity profile in early stage clinical trials conducted by GSK Biologicals. TB causes 2 million deaths a year, and is a leading cause of death among people with AIDS in the developing world.

The announcement was made during the World Conference on Lung Health in Paris, France.

Over the coming months,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2005-11-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry